Drugs for type 2 diabetes mellitus: The imperative for cardiovascular outcome assessment

Diabetes and Vascular Disease Research

Volumn 9, Issue 2, 2012, Pages 85-88

  Odette Gore, M ^a   McGuire, Darren K ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Clinical trials; Diabetes mellitus; Drug therapy; Guidelines

Indexed keywords

ACARBOSE; ALEGLITAZAR; ALOGLIPTIN; ANTIDIABETIC AGENT; CANAGLIFLOZIN; DULAGLUTIDE; EMPAGLIFLOZIN; EXENDIN 4; HEMOGLOBIN A1C; INSULIN GLARGINE; LINAGLIPTIN; LIRAGLUTIDE; LIXISENATIDE; SAXAGLIPTIN; SITAGLIPTIN;

CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; REVIEW;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DRUG APPROVAL; EVIDENCE-BASED MEDICINE; HUMANS; HYPOGLYCEMIC AGENTS; PATIENT SAFETY; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84861089439     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164112441527     Document Type: Review

References (21)

1. US Department of Health and Human Services, Centers for Disease Control and Prevention. 2011 National Diabetes Fact Sheet: National estimates and general information on diabetes and prediabetes in the United States, http://www.cdc.gov/diabetes/pubs/factsheet11.htm (2011, accessed 12 January 2012).
2. Whiting DR, Guariguata L, Weil C, et al. IDF Diabetes Atlas:Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011; 94: 311-321.
3. Shaw JE, Sicree RA and Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res ClinPract 2010; 87: 4-14.
4. King H, Aubert RE and Herman WH. Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-1431. (Pubitemid 28405191)
5. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053. (Pubitemid 38579764)
6. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: A statement for healthcare professionals from the American Heart Association. Circulation 1999; 100: 1134-1146. (Pubitemid 29416243)
7. US Department of Health and Human Services, Centers for Disease Control and Prevention. Deaths, percent of totaldeaths, and death rates for the 15 leading causes of death: United States and each state, 2008, http://www.cdc.gov/nchs/data/dvs/LCWK9-2008.pdf (2011, accessed on 1March 2012)
8. Gore MO and McGuire DK. Cardiovascular disease and type 2 diabetes mellitus: Regulating glucose and regulating drugs. Curr Cardiol Rep 2009; 11: 258-263.
9. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000; 321: 405-412. (Pubitemid 30609442)
10. Saydah S, Tao M, Imperatore G, et al. GHb level and subsequent mortality among adults in the US. Diabetes Care 2009; 32: 1440-1446.
11. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2diabetes. N Engl J Med 2008; 358: 2560-2572.
12. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes.N Engl J Med 2009; 360: 129-139.
13. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358: 2545-2559.
14. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
15. Gore MO and McGuire DK. The 10-year post-trial followup of the United Kingdom Prospective Diabetes Study (UKPDS): Cardiovascular observations in context. Diab Vasc Dis Res 2009; 6: 53-55.
16. Nissen SE and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471. (Pubitemid 46919772)
17. Nissen SE, Wolski K and Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005; 294:2581-2586. (Pubitemid 41697247)
18. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 2005; 366: 1279-1289. (Pubitemid 41416583)
19. Schramm TK, Gislason GH, Vaag A, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: A nationwide study. Eur Heart J 2011; 32: 1900-1908.
20. Gore MO and McGuire DK. Resolving drug effects from class effects among drugs for type 2 diabetes mellitus: More support for cardiovascular outcome assessments. Eur Heart J 2011; 32: 1832-1834.
21. US Department of Health and Human Services, Food and Drug Administration. Guidance for industry: diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes, http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071627.pdf (2008, accessed 12 January 2012).